3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Terminated
1
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Smoking Cessation
1
Melanoma
1
Gastrointestinal Neoplasms
1
Breast Neoplasms
1
Interventions
pembrolizumab
58
Ipilimumab
53
Cyclophosphamide
53
Nivolumab
45
aldesleukin
35
Interleukin-2
26
fludarabine phosphate
22
fludarabine
21
Vemurafenib
20
Temozolomide
19
Radiotherapy
19
dabrafenib
15
trametinib
12
Radiosurgery
11
CTLA-4 Antigen
11
spartalizumab
10
Filgrastim
10
Dacarbazine
10
cobimetinib
9
binimetinib
9
atezolizumab
9
Biopsy
9
poly ICLC
8
Paclitaxel
8
Antilymphocyte Serum
8
encorafenib
7
avelumab
7
Rituximab
7
Introns
7
romidepsin
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Cognitive Behavioral Therapy
×
Dermatologic
×
Clear all
NCT04899492
2024-11-07
RESPIRE
Institut Cancerologie de l'Ouest
Phase NA
Terminated
22 enrolled